Suchergebnisse

TargetFish is a large collaborative project unded by the European Commission under the 7th Framework Programme or Research and Technological Development (FP7) of the European Union (Grant Agreement 311993). The project that will run or 5 years, started in November 2012 and thus is approximately halway. TargetFish brings together a large number of leading European research groups (RTD) that are experts on ęsh pathology and immunology and small-to-medium enterprises (SME) as well as some larger industries rom the Biotech and Veterinary sectors, which all share a common interest and experience: vaccination of fish.

TargetFish is a large collaborative project funded by the European Commission under the 7th Framework Programme for Research and Technological Development (FP7) of the European Union (Grant Agreement 311993). The project will run for 5 years, started in November 2012 and thus is approximately halfway. TargetFish brings together a large number of leading European research groups (RTD) that are experts on fish pathology and immunology and small-to-medium enterprises (SME) as well as some larger industries from the Biotech and Veterinary sectors, which all share a common interest and experience: vaccination of fish. To achieve this challenging task, we brought together approximately 30 partners from 10 EU member states, two associated countries and one International Cooperation Partner Country (Chile). In this large multidisciplinary consortium an approximate equal number of RTD and SME partners cooperate closely while keeping an intensive communication with the vaccine and nutrition industries. The main objectives of the project are to: 1) generate knowledge by studying antigens and adjuvants for different routes of administration while analyzing the underpinning protective immune mechanisms; 2) validate this knowledge with response assays for monitoring vaccine efficacy and safety, including issues associated with DNA vaccines; 3) approach implementation of prototype vaccines shortening the route to exploitation and 4) optimize vaccination strategies in order to obtain maximum protection in different sizes of fish. At present, progress has been made in particular with regard to main objectives 1-3. The vaccine delivery systems under investigation include oral routes of administration using, for example, alginate microencapsulation and MicroMatrixTM technologies. TargetFish also focuses on investigating mucosal vaccination routes and associated immunity and in developing antigens and adjuvants specifically suited for mucosal delivery. Most fish vaccines on the market are delivered by injection, being this a labour-intensive, expensive method that provokes stress in the fish. Mucosal vaccination routes (immersion or oral) would certainly be more desirable.

We present new radio continuum images of the edge-on starburst galaxy NGC 5775, from LOFAR (140 MHz) and the Karl G. Jansky Very Large Array CHANG-ES survey (1500 MHz). We trace the non-thermal radio halo up to 13 kpc from the disc, measuring the non-thermal spectral index and estimating the total equipartition magnetic field strength (≈13 μG in the disc and ≈7 μG above the plane). The radio halo has a similar extent at both frequencies, displays evidence for localized cosmic ray streaming coinciding with prominent H α filaments and vertical extensions of the regular magnetic field, and exhibits a boxy morphology especially at 140 MHz. In order to understand the nature of the disc–halo flow, we extend our previous model of cosmic ray propagation by implementing an iso-thermal wind with a tunable 'flux tube' (approximately hyperboloidal) geometry. This updated model is successful in matching the vertical distribution of non-thermal radio emission, and the vertical steepening of the associated spectral index, in a consistent conceptual framework with few free parameters. Our new model provides the opportunity to estimate the mass outflow driven by the star formation process, and we find an implied rate of M˙≈3–6M⊙yr−1 (≈40–80 per cent of the star formation rate) if the escape velocity is reached, with substantial uncertainty arising from the poorly understood distribution of interstellar medium material entrained in the vertical flow. The wind may play a role in influencing the vertical gradient in rotational velocity. © 2021 The Author(s). ; This paper is based (in part) on data obtained with the International LOFAR Telescope (ILT) under project code LC1_046. LOFAR (van Haarlem et al. 2013) is the Low Frequency Array designed and constructed by ASTRON. It has observing, data processing, and data storage facilities in several countries, that are owned by various parties (each with their own funding sources), and that are collectively operated by the ILT foundation under a joint scientific policy. The ILT resources have benefitted from the following recent major funding sources: CNRS-INSU, Observatoire de Paris and Université d'Orléans, France; BMBF, MIWF-NRW, MPG, Germany; Science Foundation Ireland (SFI), Department of Business, Enterprise and Innovation (DBEI), Ireland; NWO, The Netherlands; The Science and Technology Facilities Council, UK; Ministry of Science and Higher Education, Poland. The National Radio Astronomy Observatory is a facility of the National Science Foundation operated under cooperative agreement by Associated Universities, Inc. GH thanks Phil Edwards for useful feedback after a critical reading of the manuscript, and Tim Galvin for advice and help with tricky plotting issues. We would like to thank B. P. Brian Yu, for kindly providing us with their computer code of the cosmic ray-driven wind model. We thank the anonymous referee for a comprehensive review and for comments that led to substantial improvements to the paper. MB acknowledges support from the Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy - EXC 2121 'Quantum Universe' - 390833306. This research was undertaken as an activity organized by the LOFAR Magnetism Key Science Project (MKSP; https://lofar-mksp.org/). ; With funding from the Spanish government through the Severo Ochoa Centre of Excellence accreditation SEV-2017-0709. ; Peer reviewed

WOS: 000319871200001 ; PubMed ID: 23198723 ; Aims: Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is a widely used biomarker of oxidative stress. However, variability between chromatographic and ELISA methods hampers interpretation of data, and this variability may increase should urine composition differ between individuals, leading to assay interference. Furthermore, optimal urine sampling conditions are not well defined. We performed inter-laboratory comparisons of 8-oxodG measurement between mass spectrometric-, electrochemical- and ELISA-based methods, using common within-technique calibrants to analyze 8-oxodG-spiked phosphate-buffered saline and urine samples. We also investigated human subject- and sample collection-related variables, as potential sources of variability. Results: Chromatographic assays showed high agreement across urines from different subjects, whereas ELISAs showed far more inter-laboratory variation and generally overestimated levels, compared to the chromatographic assays. Excretion rates in timed 'spot' samples showed strong correlations with 24 h excretion (the 'gold' standard) of urinary 8-oxodG (r(p) 0.67-0.90), although the associations were weaker for 8-oxodG adjusted for creatinine or specific gravity (SG). The within-individual excretion of 8-oxodG varied only moderately between days (CV 17% for 24 h excretion and 20% for first void, creatinine-corrected samples). Innovation: This is the first comprehensive study of both human and methodological factors influencing 8-oxodG measurement, providing key information for future studies with this important biomarker. Conclusion: ELISA variability is greater than chromatographic assay variability, and cannot determine absolute levels of 8-oxodG. Use of standardized calibrants greatly improves intra-technique agreement and, for the chromatographic assays, importantly allows integration of results for pooled analyses. If 24 h samples are not feasible, creatinine- or SG-adjusted first morning samples are recommended. ; ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5:"Food Quality and Safety" [FOOD-CT-2005-513943]; ECNIS2, a coordination and support action within the European Union FP7 Cooperation Theme 2 Food, Agriculture, Fisheries and Biotechnologies; CISBO; Ingeborg; Leo Dannin Foundation; National Science Council, TaiwanNational Science Council of Taiwan [NSC 97-2314-B-040-015-MY3, NSC 100-2628-B-040-001-MY4]; US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30ES009089]; Instituto Carlos III division of the Government for Clinical Research [PI-10/00802, RD06/0045/0006]; Generalitat ValencianaGeneralitat Valenciana [ACOM/2012/238]; Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); TUBITAK (Technical and Scientific Research Council of Turkey)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [108Y049]; Grant Agency of the Czech RepublicGrant Agency of the Czech Republic [P503/11/0084]; Sahlgrenska University Hospital, Gothenburg; UK Medical Research Council via a People Exchange Programme Research Leader Fellowship award [G1001808/98136] ; Some of the authors of this work were partners in, and this work was partly supported by, ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5:"Food Quality and Safety" (Contract No. FOOD-CT-2005-513943), and also ECNIS 2 , a coordination and support action within the European Union FP7 Cooperation Theme 2 Food, Agriculture, Fisheries and Biotechnologies.; P Moller and S Loft are supported by CISBO and the Ingeborg and Leo Dannin Foundation.; M-R Chao and C-W Hu acknowledge financial support from the National Science Council, Taiwan (Grants NSC 97-2314-B-040-015-MY3 and NSC 100-2628-B-040-001-MY4).; R Santella acknowledges the contribution of Qiao Wang, and support from US NIH P30ES009089.; G Saez and C Cerda acknowledge financial support from the Instituto Carlos III division of the Government for Clinical Research (Grants PI-10/00802 and RD06/0045/0006) and Grant ACOM/2012/238 from Generalitat Valenciana.; K Broberg, C Lindh, and M Hossain acknowledge financial support from the Swedish Council for Working Life and Social Research; H Orhan and N Senduran acknowledge financial support from TUBITAK (Technical and Scientific Research Council of Turkey), grant number 108Y049.; P Rossner, Jr. and RJ Sram acknowledge support from the Grant Agency of the Czech Republic (P503/11/0084).; L Barregard acknowledges financial support from the Sahlgrenska University Hospital, Gothenburg.; MS Cooke acknowledges support from the UK Medical Research Council via a People Exchange Programme Research Leader Fellowship award (G1001808/98136).

Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT‐P13 throughout the 78‐week study period (maintenance group) versus patients switched to CT‐P13 at week 52 (switch group). The primary outcome was disease worsening during follow‐up based on disease‐specific composite measures. Methods Patients were recruited from 24 Norwegian hospitals, 380 of 438 patients who completed the main study: 197 in the maintenance group and 183 in the switch group. In the full analysis set, 127 (33%) had Crohn's disease, 80 (21%) ulcerative colitis, 67 (18%) spondyloarthritis, 55 (15%) rheumatoid arthritis, 20 (5%) psoriatic arthritis and 31 (8%) chronic plaque psoriasis. Results Baseline characteristics were similar in the two groups at the time of switching (week 52). Disease worsening occurred in 32 (16.8%) patients in the maintenance group vs. 20 (11.6%) in the switch group (per‐protocol set). Adjusted risk difference was 5.9% (95% CI −1.1 to 12.9). Frequency of adverse events, anti‐drug antibodies, changes in generic disease variables and disease‐specific composite measures were comparable between arms. The study was inadequately powered to detect noninferiority within individual diseases. Conclusion The NOR‐SWITCH extension showed no difference in safety and efficacy between patients who maintained CT‐P13 and patients who switched from originator infliximab to CT‐P13, supporting that switching from originator infliximab to CT‐P13 is safe and efficacious.

BACKGROUND AND OBJECTIVES: The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT‐P13 throughout the 78‐week study period (maintenance group) versus patients switched to CT‐P13 at week 52 (switch group). The primary outcome was disease worsening during follow‐up based on disease‐specific composite measures. METHODS: Patients were recruited from 24 Norwegian hospitals, 380 of 438 patients who completed the main study: 197 in the maintenance group and 183 in the switch group. In the full analysis set, 127 (33%) had Crohn's disease, 80 (21%) ulcerative colitis, 67 (18%) spondyloarthritis, 55 (15%) rheumatoid arthritis, 20 (5%) psoriatic arthritis and 31 (8%) chronic plaque psoriasis. RESULTS: Baseline characteristics were similar in the two groups at the time of switching (week 52). Disease worsening occurred in 32 (16.8%) patients in the maintenance group vs. 20 (11.6%) in the switch group (per‐protocol set). Adjusted risk difference was 5.9% (95% CI −1.1 to 12.9). Frequency of adverse events, anti‐drug antibodies, changes in generic disease variables and disease‐specific composite measures were comparable between arms. The study was inadequately powered to detect noninferiority within individual diseases. CONCLUSION: The NOR‐SWITCH extension showed no difference in safety and efficacy between patients who maintained CT‐P13 and patients who switched from originator infliximab to CT‐P13, supporting that switching from originator infliximab to CT‐P13 is safe and efficacious.

Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT‐P13 throughout the 78‐week study period (maintenance group) versus patients switched to CT‐P13 at week 52 (switch group). The primary outcome was disease worsening during follow‐up based on disease‐specific composite measures. Methods Patients were recruited from 24 Norwegian hospitals, 380 of 438 patients who completed the main study: 197 in the maintenance group and 183 in the switch group. In the full analysis set, 127 (33%) had Crohn's disease, 80 (21%) ulcerative colitis, 67 (18%) spondyloarthritis, 55 (15%) rheumatoid arthritis, 20 (5%) psoriatic arthritis and 31 (8%) chronic plaque psoriasis. Results Baseline characteristics were similar in the two groups at the time of switching (week 52). Disease worsening occurred in 32 (16.8%) patients in the maintenance group vs. 20 (11.6%) in the switch group (per‐protocol set). Adjusted risk difference was 5.9% (95% CI −1.1 to 12.9). Frequency of adverse events, anti‐drug antibodies, changes in generic disease variables and disease‐specific composite measures were comparable between arms. The study was inadequately powered to detect noninferiority within individual diseases. Conclusion The NOR‐SWITCH extension showed no difference in safety and efficacy between patients who maintained CT‐P13 and patients who switched from originator infliximab to CT‐P13, supporting that switching from originator infliximab to CT‐P13 is safe and efficacious. ; publishedVersion ; Open Access CC-BY